Top news of the week from The American Journal of Pharmacy Benefits.
5. Immunotherapy Treatment Improves PFS in Advanced Triple-Negative Breast Cancer
Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer. Read more.
4. Pain Societies Create Consensus Guidelines for Use of Ketamine in Pain Management
Three pain societies have come together to create consensus guidelines for treating both acute and chronic pain with ketamine, an old drug seeing a resurgence. Read more.
3. Coffee and Chocolate May Trigger Migraines
As researchers examined what food and drinks were most commonly linked to migraine and tension-type headache in Malaysian patients, they found that coffee and chocolate were reported most often. Read more.
2. Estrogen Levels May Play a Role in Migraine Prevalence in Men
A study of 39 men found that those affected by migraine had higher levels of estradiol, an estrogen, than those without migraine. Read more.
1. Trial Demonstrates Positive Long-Term Efficacy and Safety for Migraine Drug
Amgen and Novartis have announced positive long-term efficacy, safety, and tolerability data of erenumab-aooe (Aimovig) in patients with chronic and episodic migraine. Read more.